These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22068258)

  • 1. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managed care perspective on three new agents for type 2 diabetes.
    VanDeKoppel S; Choe HM; Sweet BV
    J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
    Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK; Lereun C; Wright D
    Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatitis associated with incretin-based therapies.
    Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
    Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
    Dore DD; Seeger JD; Arnold Chan K
    Curr Med Res Opin; 2009 Apr; 25(4):1019-27. PubMed ID: 19278373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
    Harja E; Lord J; Skyler JS
    Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
    Berg JK; Shenouda SK; Heilmann CR; Gray AL; Holcombe JH
    Diabetes Obes Metab; 2011 Nov; 13(11):982-9. PubMed ID: 21615670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
    Singh S; Chang HY; Richards TM; Weiner JP; Clark JM; Segal JB
    JAMA Intern Med; 2013 Apr; 173(7):534-9. PubMed ID: 23440284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.
    Mondragon A; Davidsson D; Kyriakoudi S; Bertling A; Gomes-Faria R; Cohen P; Rothery S; Chabosseau P; Rutter GA; da Silva Xavier G
    PLoS One; 2014; 9(8):e104873. PubMed ID: 25119717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New concepts in the treatment of type 2 diabetes].
    Meier JJ; Schmidt WE; Klein HH
    Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J; Meloni A; Han J
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
    Patel MB; Elmore LK; Edgerton LP; Whalin LM
    Am J Health Syst Pharm; 2012 Jun; 69(12):1044-8. PubMed ID: 22644981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ; Moniri NH; Smiley DD
    Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.